Search Result

Isoforms Recommended:	PDE3

Results for "

PDE-3

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Phosphodiesterase (PDE) (116) Adenosine Receptor (8) Adenylate Cyclase (2) Apoptosis (18) Aurora Kinase (1) Autophagy (5) Bcl-2 Family (1) Calcium Channel (1) Caspase (1) Drug Metabolite (1) Endogenous Metabolite (17) Environmental Pollutants (1) GABA Receptor (1) HDAC (8) Histamine Receptor (4) IFNAR (1) iGluR (1) Interleukin Related (12) Isotope-Labeled Compounds (16) MAPKAPK2 (MK2) (1) Molecular Glues (3) NF-κB (2) NO Synthase (1) NOD-like Receptor (NLR) (2) Orphan GPCR (1) PARP (1) PKA (4) PPAR (1) Prostaglandin Receptor (1) Reference Standards (24) RSV (5) Small Interfering RNA (siRNA) (6) TNF Receptor (10) TRP Channel (2)
By Research Areas:	Cancer (38) Cardiovascular Disease (38) Endocrinology (16) Infection (5) Inflammation/Immunology (40) Metabolic Disease (19) Neurological Disease (21)
Oligonucleotides:	Rat Pre-designed siRNA Sets (2) Mouse Pre-designed siRNA Sets (2) Human Pre-designed siRNA Sets (2) siRNAs (6)

130

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: Phosphodiesterase (PDE)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12318

IBMX Maximum Cited Publications 69 Publications Verification 3-Isobutyl-1-methylxanthine; Isobutylmethylxanthine	Phosphodiesterase (PDE)	Inflammation/Immunology
IBMX is a broad-spectrum phosphodiesterase (PDE) inhibitor, with IC₅₀s of 6.5, 26.3 and 31.7 μM for *PDE3, PDE4* and *PDE5*, respectively.

HY-15455

Roflumilast 10+ Cited Publications APTA-2217; BYK 20869; B9302-107	Phosphodiesterase (PDE) RSV	Inflammation/Immunology
Roflumilast (APTA-2217) is a selective *PDE4* inhibitor with IC₅₀s of 0.7, 0.9, 0.7, and 0.2 nM for *PDE4A1, PDE4A4, PDE4B1, and PDE4B2, respectively, without affecting PDE1, PDE2, PDE3* or PDE5 isoenzymes from various cells.

HY-B0809

Theophylline Maximum Cited Publications 12 Publications Verification 1,3-Dimethylxanthine; Theo-24	Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Endogenous Metabolite	Infection Neurological Disease Inflammation/Immunology Cancer
Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research ^[3] .

HY-119708

Ensifentrine 1 Publications Verification RPL-554	Phosphodiesterase (PDE)	Infection Neurological Disease Inflammation/Immunology Cancer
Ensifentrine (RPL-554) is an inhaled dual inhibitor of *PDE3* and *PDE4* with IC₅₀s of 0.4 nM and 1479 nM, respectively. Ensifentrine blocks PDE3 and PDE4 enzymes, thereby increasing the levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in lung cells, dilating the bronchi, and inhibiting the activation and migration of inflammatory cells. Ensifentrine can be used in the research of chronic obstructive pulmonary disease (COPD) ^[3].

HY-B0442

Vardenafil 5 Publications Verification	Phosphodiesterase (PDE) Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-14252

Milrinone 30+ Cited Publications Win 47203	Phosphodiesterase (PDE)	Cardiovascular Disease
Milrinone is a *PDE3* inhibitor, and also an inotrope and vasodilator.

HY-101312

Cilostamide 2 Publications Verification OPC3689	Phosphodiesterase (PDE)	Cardiovascular Disease
Cilostamide is a selective and potent *PDE3* inhibitor, with IC₅₀s of 27 nM and 50 nM for PDE3A and PDE3B, respectively, and has antithrombotic and anti-intimal hyperplastic activity.

HY-B0442A

Vardenafil hydrochloride 5 Publications Verification	Phosphodiesterase (PDE) Endogenous Metabolite	Metabolic Disease Inflammation/Immunology Endocrinology Cancer
Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0204

Pimobendan 3 Publications Verification UD-CG115	Phosphodiesterase (PDE)	Cardiovascular Disease
Pimobendan (UD-CG115) is a selective inhibitor of PDE3 with IC₅₀ of 0.32 μM.

HY-163285

PDE3B-IN-1	Phosphodiesterase (PDE)	Metabolic Disease
PDE3B-IN-1 is a potent selective *PDE3B* inhibitor that demonstrates PDE3B inhibitory activity (pIC₅₀ = 6.5) and >300-fold *PDE3B/A* selectivity .

HY-109586

BRL-50481 4 Publications Verification	Phosphodiesterase (PDE)	Neurological Disease
BRL-50481 is a novel and selective inhibitor of *PDE7* with IC₅₀s of 0.15, 12.1, 62 and 490 μM for *PDE7A, PDE7B, PDE4* and *PDE3*, respectively.

HY-B0523

Anagrelide 3 Publications Verification	Phosphodiesterase (PDE) Apoptosis	Cardiovascular Disease Cancer
Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36 nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action ^[3].

HY-B0523A

Anagrelide hydrochloride 3 Publications Verification BL4162A	Phosphodiesterase (PDE) Apoptosis	Cardiovascular Disease Cancer
Anagrelide hydrochloride (BL4162A) is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36 nM). Anagrelide hydrochloride, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide hydrochloride inhibits bone marrow megakaryocytopoiesis. Anagrelide hydrochloride decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide hydrochloride is a platelet-lowering agent and plays in the antithrombopoietic action ^[3].

HY-B0442B

Vardenafil hydrochloride trihydrate 5 Publications Verification	Endogenous Metabolite Phosphodiesterase (PDE)	Metabolic Disease Inflammation/Immunology Endocrinology
Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-14254A

Olprinone 1 Publications Verification Loprinone	Phosphodiesterase (PDE)	Cardiovascular Disease
Olprinone (Loprinone) is a potent phosphodiesterase (PDE) 3 inhibitor, with IC₅₀s of 150, 100, 0.35 and 14 μM for PDE1, PDE2, PDE3 and PDE4, respectively. Olprinone is used for the research of heart failure due to its positive inotropic and vasodilative effects. Anti-inflammatory activity .

HY-15297

Vesnarinone 2 Publications Verification OPC-8212	Phosphodiesterase (PDE)	Infection Cardiovascular Disease
Vesnarinone (OPC-8212) is an orally active phosphodiesterase 3 (PDE3) inhibitor. Vesnarinone can increase in calcium flux and decrease in potassium flux. Vesnarinone shows dose-dependent positive inotropic activity. Vesnarinone can be used in heart failure research ^[3] .

HY-15485

Zardaverine 1 Publications Verification	Phosphodiesterase (PDE) Apoptosis	Inflammation/Immunology Cancer
Zardaverine is an orally active and selective *PDE3/4* inhibitor (IC₅₀)=0.58 uM/0.17 uM) with potent bronchodilator activity. Zardaverine also selectively inhibits the proliferation of HCC cells and induces apoptosis and cycle arrest (G0/G1 phase). Zardaverine has good antitumor potential and is effective in both bronchial relaxation and reduction of inflammation in asthma ^[3].

HY-B1639

Enoximone	Phosphodiesterase (PDE)	Cardiovascular Disease Inflammation/Immunology
Enoximone is an inotropic vasodilating agent and a selective and orally active phosphodiesterase III (PDE3) inhibitor with an IC₅₀ of 5.9 μM. Enoximone induces vasodilatation and increases intracellular levels of cAMP by inhibiting cGMP-inhibited PDE. Enoximone also exhibits *PDE4* inhibitory effect with an IC₅₀ of 21.1 μM for myocardial PDE4A. Enoximone has the potential for congestive heart failure research and has bronchodilatory, antiasthma and anti-inflammatory effects ^[3].

HY-10790

Cilomilast 3 Publications Verification SB-207499	Phosphodiesterase (PDE)	Inflammation/Immunology
Cilomilast (SB-207499) is a potent, selective and orally active inhibitor of Phosphodiesterase 4 (PDE4), with IC₅₀s of ~100 and 120 nM for LPDE4 and HPDE4, respectively. Cilomilast shows selectivity for PDE4 over PDE1, PDE2, PDE3 and PDE5 (IC₅₀=74, 65, >100, and 83 μM, respectively). Cilomilast has anti-inflammatory and immunomodulatory effects and can be used for thr research of asthma and chronic obstructive pulmonary disease (COPD) ^[3].

HY-136350

BRD9500	Phosphodiesterase (PDE)	Cancer
BRD9500 is an orally active phosphodiesterases 3 (PDE3) inhibitor with IC₅₀s of 10 and 27 nM for *PDE3A* and *PDE3B*, respectively. Antitumor activity .

HY-14254

Olprinone Hydrochloride 1 Publications Verification Loprinone Hydrochloride	Phosphodiesterase (PDE)	Cardiovascular Disease
Olprinone (Loprinone) Hydrochloride is a potent phosphodiesterase (PDE) 3 inhibitor, with IC₅₀s of 150, 100, 0.35 and 14 μM for PDE1, PDE2, PDE3 and PDE4, respectively. Olprinone Hydrochloride is used for the research of heart failure due to its positive inotropic and vasodilative effects. Anti-inflammatory activity .

HY-102050

PF-05085727	Phosphodiesterase (PDE)	Neurological Disease
PF-05085727 is a potent, selective and brain penetrant inhibitor of cGMP-dependent *PDE2A* (IC₅₀=2 nM). PF-05085727 inhibits PDE2A >4,000-fold selectivity over PDE1 and PDE3-11 .

HY-18740A

Trequinsin hydrochloride HL 725	Phosphodiesterase (PDE)	Neurological Disease Metabolic Disease Cancer
Trequinsin hydrochloride (HL 725) is a *PDE* inhibitor, CatSper channel activator, and sperm potassium channel modulator. Trequinsin hydrochloride targets *PDE3* with an IC₅₀ of <1 nM. Trequinsin hydrochloride enhances currents and elevates intracellular calcium and cGMP levels via direct activation of the CatSper channel, while inhibiting the outward current conductance of sperm potassium channels. Without inducing premature acrosome reaction, Trequinsin hydrochloride significantly enhances sperm hyperactivated motility, forward motility, and the ability to penetrate viscous media. Trequinsin hydrochloride exerts age-specific positive inotropic and positive lusitropic effects on rabbit ventricular papillary muscles. Trequinsin hydrochloride has been used in studies on the mechanisms underlying male infertility (e.g., asthenozoospermia) .

HY-145924

BAY 2666605 3 Publications Verification	Phosphodiesterase (PDE)	Cancer
BAY 2666605 is an orally active *PDE3A* and *PDE3B* inhibitor with IC₅₀s of 87 nM and 50 nM, respectively. BAY 2666605 is a *PDE3A-SLFN12* complex inducer (WO2019025562A1; example 135) .

HY-A0027

Fenspiride hydrochloride	Histamine Receptor Phosphodiesterase (PDE)	Inflammation/Immunology Endocrinology
Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC₅₀ values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases ^[3].

HY-B0809A

Theophylline monohydrate 5+ Cited Publications 1,3-Dimethylxanthine monohydrate; Theo-24 monohydrate	Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor	Cancer
Theophylline (1,3-Dimethylxanthine) monohydrate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) monohydrate inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) monohydrate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) monohydrate induces apoptosis. Theophylline (1,3-Dimethylxanthine) monohydrate can be used for asthma and chronic obstructive pulmonary disease (COPD) research ^[3] .

HY-U00186

K134 OPC33509	Phosphodiesterase (PDE)	Cardiovascular Disease
K134 is a phosphodiesterase 3 (PDE3) inhibitor. The IC₅₀s of K134 toward *PDE3A, PDE3B, PDE5, PDE2 and PDE*4 are 0.1, 0.28, 12.1, >300 and >300 µM, respectively.

HY-12318R

IBMX (Standard) 3-Isobutyl-1-methylxanthine (Standard); Isobutylmethylxanthine (Standard)	Reference Standards Phosphodiesterase (PDE)	Inflammation/Immunology
IBMX (Standard) is the analytical standard of IBMX. This product is intended for research and analytical applications. IBMX is a broad-spectrum phosphodiesterase (PDE) inhibitor, with IC50s of 6.5, 26.3 and 31.7 μM for PDE3, PDE4 and PDE5, respectively.

HY-174383

PDE3/4-IN-2	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE3/4-IN-2 is a dual *PDE3A* and *PDE4B1* inhibitor, with an IC₅₀ of 0.13 nM against *PDE3A* and 50 nM against *PDE4B1. PDE3/4-IN-2 exhibits higher systemic exposure and longer retention time in lung tissues in ICR mice. PDE3*/4-IN-2 can be used in research on respiratory diseases such as asthma and chronic obstructive pulmonary disease, as well as autoimmune inflammation-related studies .

HY-B0809R

Theophylline (Standard) 5+ Cited Publications 1,3-Dimethylxanthine(Standard); Theo-24 (Standard)	Reference Standards Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Endogenous Metabolite	Cancer
Theophylline (Standard) is the analytical standard of Theophylline. This product is intended for research and analytical applications. Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research ^[3] .

HY-111477

(E/Z)-Ensifentrine (E/Z)-RPL-554	Phosphodiesterase (PDE)	Neurological Disease
(E/Z)-Ensifentrine is a dual inhibitor of *PDE3/4*. (E/Z)-Ensifentrine reduces the inflammatory cells into the airways. (E/Z)-Ensifentrine has bronchodilatory and anti-inflammatory activities in vitro and in vivo model .

HY-B1514R

Allantoic acid (Standard)	Reference Standards Endogenous Metabolite	Others
Anagrelide (hydrochloride) (Standard) is the analytical standard of Anagrelide (hydrochloride). This product is intended for research and analytical applications. Anagrelide hydrochloride (BL4162A) is a potent inhibitor of phosphodiesterase type III (PDE3) (IC50=36 nM). Anagrelide hydrochloride, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide hydrochloride inhibits bone marrow megakaryocytopoiesis. Anagrelide hydrochloride decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide hydrochloride is a platelet-lowering agent and plays in the antithrombopoietic action ^[3].

HY-106739

Motapizone NAT 05-239	Phosphodiesterase (PDE)	Inflammation/Immunology
Motapizone (NAT 05-239) is a selective *PDE3* inhibitor. Motapizone moderately inhibits cytokine release in lipopolysaccharide (LPS)-induced alveolar macrophages. Motapizone also inhibits human platelet aggregation by increasing intracellular cAMP .

HY-B0204S1

Pimobendan-d3 UD-CG115-d₃	Isotope-Labeled Compounds Phosphodiesterase (PDE)	Cardiovascular Disease
Pimobendan-d₃ (UD-CG115-d₃) is deuterium labeled Pimobendan (HY-B0204). Pimobendan (UD-CG115) is a selective inhibitor of PDE3 with IC₅₀ of 0.32 μM .

HY-15455S

Roflumilast-d4 1 Publications Verification APTA-2217-d₄; BYK 20869-d₄; B9302-107-d₄	Isotope-Labeled Compounds Phosphodiesterase (PDE) RSV	Inflammation/Immunology
Roflumilast-d₄ is the deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC₅₀s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells .

HY-176524S

PDE3/4-IN-3	Phosphodiesterase (PDE)	Inflammation/Immunology
PDE3/4-IN-3 (Compound 7) is an orally active dual *PDE3/4* inhibitor with IC₅₀s of 0.17 and ≤50 nM for PDE3A and PDE4B2, respectively. PDE3/4-IN-3 significantly inhibits methacholine-induced bronchoconstriction in guinea pigs. PDE3/4-IN-3 can be used for chronic obstructive pulmonary disease (COPD) and asthma research .

HY-107909

Theophylline sodium glycinate 1,3-Dimethylxanthine sodium glycinate; Theo-24 sodium glycinate	Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor	Cancer
Theophylline (1,3-Dimethylxanthine) sodium glycinate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline sodium glycinate inhibits PDE3 activity to relax airway smooth muscle. Theophylline sodium glycinate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline sodium glycinate induces apoptosis. Theophylline sodium glycinate can be used for asthma and chronic obstructive pulmonary disease (COPD) research ^[3] .

HY-B0442AS

Vardenafil-d5 hydrochloride	Endogenous Metabolite Phosphodiesterase (PDE) Isotope-Labeled Compounds	Metabolic Disease Inflammation/Immunology Endocrinology
Vardenafil-d₅ hydrochloride is deuterated labeled Vardenafil hydrochloride (HY-B0442A). Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-19102

NSP-805	Phosphodiesterase (PDE)	Cardiovascular Disease
NSP-805 is a potent and selective inhibitor of guinea pig cardiac phosphodiesterase 3 (PDE3), and a cardiotonic agent with vasodilator properties.

HY-131545

Parogrelil NT-702 free base; NT-702 free base	Phosphodiesterase (PDE)	Others
Parogrelil (NT-702 free base) is a compound with intermittent claudication inhibitory activity that inhibits PDE3, inhibits platelet aggregation and vasoconstriction, and improves walking distance and plantar surface temperature in a rat experimental model.

HY-103024

ICI-63197	Environmental Pollutants Phosphodiesterase (PDE)	Neurological Disease
ICI-63197 is a phosphodiesterase 3 (PDE3) and *PDE4* inhibitor with K_i values of 9 µM and 10 µM, respectively. ICI-63197 is selectivity against PDE1 and PDE2. ICI-63197 has antidepressant effects .

HY-112631

OPC 33540	Phosphodiesterase (PDE)	Cardiovascular Disease
OPC-33540 is a highly selective and competitive *PDE3* inhibitor with IC₅₀ values of 0.32 nM (PDE3A) and 1.5 nM (PDE3B). OPC-33540 exhibits IC₅₀s against PDE1, PDE2, PDE4, PDE5, and PDE7 of 42.9, 52.3, 100.8, 2.5, and 51.3 μM, respectively. OPC-33540 significantly enhances cAMP accumulation in platelets and effectively inhibits thrombin-induced platelet aggregation. OPC-33540 can be used in antithrombotic studies .

HY-15455R

Roflumilast (Standard) APTA-2217 (Standard); BYK 20869 (Standard); B9302-107 (Standard)	Reference Standards Phosphodiesterase (PDE) RSV	Inflammation/Immunology
Roflumilast (Standard) is the analytical standard of Roflumilast. This product is intended for research and analytical applications. Roflumilast (APTA-2217) is a selective *PDE4* inhibitor with IC₅₀s of 0.7, 0.9, 0.7, and 0.2 nM for *PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3* or PDE5 isoenzymes from various cells.

HY-119708S

Ensifentrine-d6 RPL-554-d₆	Isotope-Labeled Compounds Phosphodiesterase (PDE)	Inflammation/Immunology
Ensifentrine-d₆ (RPL-554-d₆) is deuterium labeled Ensifentrine. Ensifentrine (RPL-554) is an inhaled first-in-class dual inhibitor of phosphodiesterase 3 (PDE3) and *PDE4* with IC₅₀s of 0.4 nM and 1479 nM, respectively. Ensifentrine has bronchoprotective and anti-inflammatory activities. Ensifentrine can be used for chronic obstructive pulmonary disease (COPD) research .

HY-116540A

L 858051 dihydrochloride 7DMB-Forskolin	Adenylate Cyclase	Cardiovascular Disease
L 858051 (7DMB-Forskolin) dihydrochloride, an analog of Forskolin (HY-15371), is an adenylyl cyclase stimulator. L 858051 dihydrochloride directly activates adenylyl cyclase to increase intracellular, cellular, and ciliary cAMP levels. L 858051 dihydrochloride activates recombinant cyclic nucleotide-gated (E583M CNGA2) channels to induce a non-selective, Mg ²⁺-sensitive current in adult rat ventricular myocytes. L 858051 dihydrochloride maximally stimulates L-type Ca ²⁺ current in adult rat ventricular myocytes. L 858051 dihydrochloride increases total PDE3 and PDE4 activities in adult rat ventricular myocytes, with effects insensitive to PKA inhibition. L 858051 dihydrochloride serves as a tool to elevate intracellular cAMP for studying subsarcolemmal cAMP dynamics and compartmentation in adult rat ventricular myocytes ^[3].

HY-B0204A

Pimobendan hydrochloride UD-CG115 hydrochloride	Phosphodiesterase (PDE)	Cardiovascular Disease
Pimobendan hydrochloride (UD-CG115 hydrochloride) is a selective inhibitor of PDE3 with IC₅₀ of 0.32 μM.

HY-101312R

Cilostamide (Standard) OPC3689 (Standard)	Reference Standards Phosphodiesterase (PDE)	Cardiovascular Disease
Cilostamide (Standard) is the analytical standard of Cilostamide. This product is intended for research and analytical applications. Cilostamide is a selective and potent PDE3 inhibitor, with IC50s of 27 nM and 50 nM for PDE3A and PDE3B, respectively, and has antithrombotic and anti-intimal hyperplastic activity.

HY-14252S

Milrinone-d3	Isotope-Labeled Compounds Phosphodiesterase (PDE)	Cardiovascular Disease
Milrinone-d₃ is deuterium labeled Milrinone. Milrinone is a PDE3 inhibitor, and also an inotrope and vasodilator.

HY-136350B

(S)-BRD9500	Phosphodiesterase (PDE)	Cancer
(S)-BRD9500 is the isomer of BRD9500 (HY-136350), and can be used as an experimental control. BRD9500 is an orally active phosphodiesterases 3 (PDE3) inhibitor with IC₅₀s of 10 and 27 nM for *PDE3A* and *PDE3B*, respectively. Antitumor activity .

HY-14252R

Milrinone (Standard) Win 47203 (Standard)	Reference Standards Phosphodiesterase (PDE)	Cardiovascular Disease
Milrinone (Standard) is the analytical standard of Milrinone. This product is intended for research and analytical applications. Milrinone is a *PDE3* inhibitor, and also an inotrope and vasodilator.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0809

Theophylline Maximum Cited Publications 12 Publications Verification 1,3-Dimethylxanthine; Theo-24	Structural Classification Classification of Application Fields Camellia sinensis (L.) O. Ktze. Plants Endogenous metabolite Alkaloids Immune System Disorder Other Alkaloids Disease markers Disease Research Fields Source Classification Theaceae Cancer	Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Endogenous Metabolite
Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research ^[3] .

HY-B0442

Vardenafil 5 Publications Verification	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0442A

Vardenafil hydrochloride 5 Publications Verification	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-B0442B

Vardenafil hydrochloride trihydrate 5 Publications Verification	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-A0027

Fenspiride hydrochloride	Classification of Application Fields Disease Research Fields Endocrinology	Histamine Receptor Phosphodiesterase (PDE)
Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC₅₀ values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases ^[3].

HY-B0809A

Theophylline monohydrate 5+ Cited Publications 1,3-Dimethylxanthine monohydrate; Theo-24 monohydrate	Structural Classification Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor
Theophylline (1,3-Dimethylxanthine) monohydrate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) monohydrate inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) monohydrate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) monohydrate induces apoptosis. Theophylline (1,3-Dimethylxanthine) monohydrate can be used for asthma and chronic obstructive pulmonary disease (COPD) research ^[3] .

HY-B0809R

Theophylline (Standard) 5+ Cited Publications 1,3-Dimethylxanthine(Standard); Theo-24 (Standard)	Alkaloids Immune System Disorder Classification of Application Fields Disease markers Camellia sinensis (L.) O. Ktze. Plants Endogenous metabolite Disease Research Fields Source Classification Theaceae Cancer	Reference Standards Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor Endogenous Metabolite
Theophylline (Standard) is the analytical standard of Theophylline. This product is intended for research and analytical applications. Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research ^[3] .

HY-B1514R

Allantoic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
Anagrelide (hydrochloride) (Standard) is the analytical standard of Anagrelide (hydrochloride). This product is intended for research and analytical applications. Anagrelide hydrochloride (BL4162A) is a potent inhibitor of phosphodiesterase type III (PDE3) (IC50=36 nM). Anagrelide hydrochloride, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide hydrochloride inhibits bone marrow megakaryocytopoiesis. Anagrelide hydrochloride decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide hydrochloride is a platelet-lowering agent and plays in the antithrombopoietic action ^[3].

HY-N10149

Nauclefine	Alkaloids Nauclea officinalis (Pirre ex Pitard) Merr. Rubiaceae Plants Indole Alkaloids Source Classification	Phosphodiesterase (PDE) Apoptosis
Nauclefine is an indole alkaloid isolated from Nauclea officinalis. Nauclefine acts as a *PDE3A* modulator to induce cancer cell apoptosis through a PDE3A-SLFN12-dependent death pathway .

HY-B0442C

Vardenafil dihydrochloride	Natural Products Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Endocrinology Source Classification	Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM respectively, while IC₅₀s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^- .

HY-B0442CR

Vardenafil dihydrochloride (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-B0442AR

Vardenafil hydrochloride (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Phosphodiesterase (PDE) Endogenous Metabolite Reference Standards
Vardenafil (hydrochloride) (Standard) is the analytical standard of Vardenafil (hydrochloride). This product is intended for research and analytical applications. Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-B0442R

Vardenafil (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Phosphodiesterase (PDE) Endogenous Metabolite
Vardenafil (Standard) is the analytical standard of Vardenafil. This product is intended for research and analytical applications. Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-W049735R

N,N,O-Tridesmethylvenlafaxine (Standard)	Monophenols Phenols Endogenous metabolite Source Classification	Drug Metabolite Reference Standards Endogenous Metabolite
Vardenafil (dihydrochloride) (Standard) is the analytical standard of Vardenafil (dihydrochloride). This product is intended for research and analytical applications. Vardenafil dihydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil dihydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM respectively, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil dihydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil dihydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-B0809B

Theophylline sodium acetate 1,3-Dimethylxanthine sodium acetate; Theo-24 sodium acetate	Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	Endogenous Metabolite Phosphodiesterase (PDE) Adenosine Receptor HDAC Apoptosis Interleukin Related TNF Receptor
Theophylline (1,3-Dimethylxanthine) sodium acetate is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) sodium acetate inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) sodium acetate has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) sodium acetate induces apoptosis. Theophylline (1,3-Dimethylxanthine) sodium acetate can be used for asthma and chronic obstructive pulmonary disease (COPD) research ^[3] .

HY-B0442BR

Vardenafil hydrochloride trihydrate (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Phosphodiesterase (PDE)
Vardenafil (hydrochloride trihydrate) (Standard) is the analytical standard of Vardenafil (hydrochloride trihydrate). This product is intended for research and analytical applications. Vardenafil hydrochloride trihydrate is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride trihydrate shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride trihydrate competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride trihydrate can be used for the research of erectile dysfunction, hepatitis, diabetes - .

HY-N11965

4'-Methoxyisoagarotetrol	Natural Products Thymelaeaceae Plants Aquilaria sinensis (Lour.) Spreng. Source Classification	Phosphodiesterase (PDE)
4'-Methoxyisoagarotetrol is chromone derivative and shows moderate *PDE 3A* inhibitory activity (IC₅₀=54 μM) .

HY-N17617

S-Petasin	Structural Classification Natural Products Plants Petasites hybridus (L.) G.Gaertn., B.Mey. & Schreb. Compositae Source Classification	Phosphodiesterase (PDE) Apoptosis NO Synthase Caspase PPAR Bcl-2 Family PARP
S-Petasin is a phosphodiesterase (PDE) inhibitor with IC₅₀ values of 25.5 μM and 17.5 μM for *PDE3* and *PDE4, respectively. S-Petasin inhibits cholesterol side-chain cleavage enzyme, 11β-hydroxylase, PPAR-γ, and iNOS* induction at RNA and protein levels. S-Petasin induces apoptosis, activates caspases, cleaves PARP, modulates mitochondrial membrane permeability, and regulates BCL2/BAX, p53, Bcl-XL, MMP-2, MMP-9, p21, CDK4, and cyclin D1 expression. S-Petasin reduces inflammatory cell accumulation, cytokine and IgE levels, and enhances serum IgG2a levels. S-Petasin relaxes isolated sensitized guinea pig trachealis and exhibits gastrointestinal anti-spasmodic activity. S-Petasin reduces tonsillitis severity and asthmatic attack frequency. S-Petasin can be used for the research of prostate cancer, obesity, melanoma, allergic asthma, asthma, and peritonitis ^[3] .

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P75961

	PDE3A Protein, Human (sf9, His-GST) cGMP-inhibited 3',5'-cyclic phosphodiesterase A; CGI-PDE A; PDE3A	Human	Sf9 insect cells
	PDE3A protein, a cyclic nucleotide phosphodiesterase, targets cAMP, cGMP, and cUMP, crucial in diverse physiological processes. In an E2/17beta-estradiol-induced pro-apoptotic pathway, E2 stabilizes the PDE3A/SLFN12 complex, leading to SLFN12 dephosphorylation and activating its pro-apoptotic ribonuclease activity. This pathway is implicated in tissues with high E2 concentrations, potentially contributing to processes like placenta remodeling. PDE3A Protein, Human (sf9, His-GST) is the recombinant human-derived PDE3A protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-B0204S1

Pimobendan-d3
Pimobendan-d₃ (UD-CG115-d₃) is deuterium labeled Pimobendan (HY-B0204). Pimobendan (UD-CG115) is a selective inhibitor of PDE3 with IC₅₀ of 0.32 μM .

HY-15455S

Roflumilast-d4 1 Publications Verification
Roflumilast-d₄ is the deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC₅₀s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells .

HY-176524S

PDE3/4-IN-3
PDE3/4-IN-3 (Compound 7) is an orally active dual *PDE3/4* inhibitor with IC₅₀s of 0.17 and ≤50 nM for PDE3A and PDE4B2, respectively. PDE3/4-IN-3 significantly inhibits methacholine-induced bronchoconstriction in guinea pigs. PDE3/4-IN-3 can be used for chronic obstructive pulmonary disease (COPD) and asthma research .

HY-B0442AS

Vardenafil-d5 hydrochloride

Vardenafil-d₅ hydrochloride is deuterated labeled Vardenafil hydrochloride (HY-B0442A). Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC₅₀s of 180 nM, and 11 nM, while IC₅₀s are >1000 nM for PDE3 and PDE4 . Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels . Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes ^[1]-[6].

HY-119708S

Ensifentrine-d6
Ensifentrine-d₆ (RPL-554-d₆) is deuterium labeled Ensifentrine. Ensifentrine (RPL-554) is an inhaled first-in-class dual inhibitor of phosphodiesterase 3 (PDE3) and *PDE4* with IC₅₀s of 0.4 nM and 1479 nM, respectively. Ensifentrine has bronchoprotective and anti-inflammatory activities. Ensifentrine can be used for chronic obstructive pulmonary disease (COPD) research .

HY-17464S1

Cilostazol-d4
Cilostazol-d₄ is deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC₅₀ of 0.2 μM .

HY-14252S

Milrinone-d3
Milrinone-d₃ is deuterium labeled Milrinone. Milrinone is a PDE3 inhibitor, and also an inotrope and vasodilator.

HY-B0204S2

Pimobendan-d4
Pimobendan-d₄ (UD-CG115-d₄) is deuterium labeled Pimobendan (HY-B0204). Pimobendan (UD-CG115) is a selective inhibitor of PDE3 with IC₅₀ of 0.32 μM .

HY-15455S2

Roflumilast-d3
Roflumilast-d₃ is deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells.

HY-15455S1

Roflumilast-d4 N-Oxide
Roflumilast-d₄ N-Oxide is the deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC₅₀s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells .

HY-B0442S

Vardenafil-d5

Vardenafil-d₅ is deuterium labeled Vardenafil. Vardenafil is a selective, orally active, potent inhibitor of phosphodiesterase-5 (PDE5), with an IC₅₀ of 0.7 nM. Vardenafil shows selectivity over PDE1 (180 nM), PDE6 (11 nM), PDE2, PDE3, and PDE4 (>1000 nM). Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil can be used for the research of erectile dysfunction .

HY-A0027AS

Fenspiride-d5

Fenspiride-d₅ is the deuterium labeled Fenspiride. Fenspiride, an orally active non-steroidal antiinflammatory agent, is an antagonist of H1-histamine receptor. Fenspiride inhibites phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4) and phosphodiesterase 5 (PDE5) activities with -log IC₅₀ values of 3.44, 4.16 and approximately 3.8, respectively. Fenspiride can be used for the research of respiratory diseases ^[3].

HY-B0523S

Anagrelide-13C2,15N,d2

Anagrelide- ¹³C₂, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Anagrelide (HY-B0523). Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36 nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action ^[3].

HY-B0809S1

Theophylline-d3

Theophylline-d₃ is deuterated labeled Theophylline (HY-B0809). Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research ^[3] .

HY-143683S

Theophylline-13C2,d6

Theophylline- ¹³C₂,d₆ (1,3-Dimethylxanthine- ¹³C₂,d₆) is the deuterium labeled and ¹³C-labeled Theophylline (HY-B0809). Theophylline (1,3-Dimethylxanthine) is a potent phosphodiesterase (PDE) inhibitor, adenosine receptor antagonist, and histone deacetylase (HDAC) activator. Theophylline (1,3-Dimethylxanthine) inhibits PDE3 activity to relax airway smooth muscle. Theophylline (1,3-Dimethylxanthine) has anti-inflammatory activity by increase IL-10 and inhibit NF-κB into the nucleus. Theophylline (1,3-Dimethylxanthine) induces apoptosis. Theophylline (1,3-Dimethylxanthine) can be used for asthma and chronic obstructive pulmonary disease (COPD) research ^[3] .

HY-17464S

Cilostazol-d11
Cilostazol-d₁₁ is the deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC₅₀ of 0.2 μM .

HY-17464S2

Cilostazol-d2
Cilostazol-d₂ (OPC 13013-d₂) is deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC₅₀ of 0.2 μM .

HY-17464S3

Cilostazol-d6
Cilostazol-d₆ (OPC 13013-d₆) is deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC₅₀ of 0.2 μM .

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P810276

	PDE3A Antibody (YA9620)	WB, ICC/IF, IF-Tissue, IP, ELISA	human, mouse, rat
	PDE3A Antibody (YA9620) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to PDE3A.